Core Insights - Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., received a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation [1] - This score is the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year's report [1] Company Performance - The AMR Benchmark evaluates pharmaceutical companies' efforts in combating antimicrobial resistance, highlighting Innoviva's commitment to infectious disease therapeutics [1]